Originally published by our sister publication Clinical Oncology News
Clinical Oncology News Staff
The FDA has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
Efficacy was evaluated in CheckMate 9DW (ClinicalTrials.gov Identifier: NCT04039607), a randomized (1:1), open-label trial in 668 adults with unresectable or metastatic HCC. Patients